Increased Proinflammatory Cytokines, Executive Dysfunction, and Reduced Gray Matter Volumes In First-Episode Bipolar Disorder and Major Depressive Disorder

被引:46
作者
Chen, Mu-Hong [1 ,5 ,6 ]
Kao, Zih-Kai [2 ]
Chang, Wan-Chen [2 ]
Tu, Pei-Chi [1 ,2 ,3 ,4 ]
Hsu, Ju-Wei [1 ,6 ]
Huang, Kai-Lin [1 ,6 ]
Su, Tung-Ping [1 ,4 ,5 ,6 ,7 ]
Li, Cheng-Ta [1 ,5 ,6 ]
Lin, Wei-Chen [1 ,5 ,6 ]
Tsai, Shih-Jen [1 ,5 ,6 ]
Bai, Ya-Mei [1 ,5 ,6 ]
机构
[1] Taipei Vet Gen Hosp, Dept Psychiat, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan
[3] Natl Yang Ming Univ, Inst Philosophy Mind & Cognit, Taipei, Taiwan
[4] Natl Yang Ming Univ, Fac Med, Div Psychiat, Taipei, Taiwan
[5] Natl Yang Ming Univ, Inst Brain Sci, Taipei, Taiwan
[6] Natl Yang Ming Univ, Sch Med, Div Psychiat, Taipei, Taiwan
[7] Gen Cheng Hsin Hosp, Dept Psychiat, Taipei, Taiwan
关键词
Systemic inflammation; Executive dysfunction; Gray matter volume; First episode; Bipolar disorder; Major depressive disorder; CORTICAL THICKNESS; FAMILIAL RISK; 1ST EPISODE; METAANALYSIS; SCHIZOPHRENIA; ADOLESCENTS; UNIPOLAR; IMPAIRMENT; DEFICITS; SUBTYPES;
D O I
10.1016/j.jad.2020.05.158
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Backgrounds: The association between systemic inflammation, executive dysfunction, and gray matter (GM) volume difference in first-episode affective disorders, including bipolar and major depressive disorders, is unclear. Methods: Twenty-two patients with first-episode bipolar disorder, 22 age- and sex-matched patients with first-episode major depressive disorder, and 22 matched controls were enrolled in our study; all patients underwent comprehensive assessments, including clinical assessment, executive function examination (Wisconsin card sorting test [WCST]), proinflammatory cytokine receptors (soluble interleukin-6 receptor and tumor necrosis factor-alpha receptor 1 [TNFR1]), and brain magnetic resonance imaging. Voxel-based morphometry was performed to analyze the GM volume difference between bipolar and major depressive disorders. Results: Patients with bipolar disorder were more likely to exhibit higher levels of TNFR1 (P = .038), more number of deficits in WCST (P < .05), and smaller GM volume in the middle frontal cortex (uncorrected voxel level P < .001) compared with those with major depressive disorder and healthy controls. Positive associations were observed between the middle frontal cortex volume, executive function, and the TNFR1 level. Discussion: GM volume reduction in the middle frontal cortex, a greater level of systemic inflammation, and executive dysfunction were observed in first-episode affective disorders, especially bipolar disorder. A positive correlation between middle frontal cortex volume, executive function, and the TNFR1 level may indicate a divergent effect of brain and systemic inflammation functioning in the early phase (first episode) of affective disorder.
引用
收藏
页码:825 / 831
页数:7
相关论文
共 50 条
  • [41] Cerebral and cerebellar gray matter reduction in first-episode patients with major depressive disorder: A voxel-based morphometry study
    Peng, Jing
    Liu, Jiangtao
    Nie, Binbin
    Li, Yang
    Shan, Baoci
    Wang, Gang
    Li, Kuncheng
    EUROPEAN JOURNAL OF RADIOLOGY, 2011, 80 (02) : 395 - 399
  • [42] Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: Population-based study Metabolic syndrome in current depressive episode
    Moreira, Fernanda Pedrotti
    Jansen, Karen
    Cardoso, Taiane de Azevedo
    Mondin, Thaise Campos
    da Silva Magalhaes, Pedro Vieira
    Kapczinski, Flavio
    de Mattos Souza, Luciano Dias
    da Silva, Ricardo Azevedo
    Oses, Jean Pierre
    Wiener, Carolina David
    JOURNAL OF PSYCHIATRIC RESEARCH, 2017, 92 : 119 - 123
  • [43] First episode drug-naive major depressive disorder with panic disorder: Gray matter deficits in limbic and default network structures
    Lai, Chien-Han
    Hsu, Yuan-Yu
    Wu, Yu-Te
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 (10) : 676 - 682
  • [44] Memory and processing speed impairments in first-episode drug-na?ve patients with major depressive disorder
    Hu, Yongbo
    Li, Jin
    Zhao, Youjin
    Dong, Zaiquan
    Qiu, Peiyuan
    Yang, Shujuan
    Xu, Haizhen
    Kuang, Weihong
    Gong, Qiyong
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 322 : 99 - 107
  • [45] COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder
    Otsuka, Yuka
    Kakeda, Shingo
    Sugimoto, Koichiro
    Katsuki, Asuka
    Le Hoa Nguyen
    Igata, Ryohei
    Watanabe, Keita
    Ueda, Issei
    Kishi, Taro
    Iwata, Nakao
    Korogi, Yukunori
    Yoshimura, Reiji
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 1537 - 1545
  • [46] Desynchronized white matter function and structure in drug-naive first-episode major depressive disorder patients
    Guo, Qinger
    Duan, Jingfeng
    Cai, Shuyang
    Zhang, Jiaxi
    Chen, Tao
    Yang, Hong
    FRONTIERS IN PSYCHIATRY, 2023, 13
  • [47] Differences in gray matter volumes of subcortical nuclei between major depressive disorder with and without persistent depressive disorder
    Hung, Ching-, I
    Wu, Chen-Te
    Chao, Yi-Ping
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 321 : 161 - 166
  • [48] Gray matter biomarkers for major depressive disorder and manic disorder using logistic regression
    Kumar, Mukesh
    Goyal, Prashant
    Sagar, Rajesh
    Kumaran, S. Senthil
    JOURNAL OF PSYCHIATRIC RESEARCH, 2024, 171 : 177 - 184
  • [49] A comparison study of metabolic profiles, immunity, and brain gray matter volumes between patients with bipolar disorder and depressive disorder
    Bai, Ya-Mei
    Chen, Mu-Hong
    Hsu, Ju-Wei
    Huang, Kai-Lin
    Tu, Pei-Chi
    Chang, Wan-Chen
    Su, Tung-Ping
    Li, Cheng Ta
    Lin, Wei-Chen
    Tsai, Shih-Jen
    JOURNAL OF NEUROINFLAMMATION, 2020, 17 (01)
  • [50] Reactive heart rate variability in male patients with first-episode major depressive disorder
    Liang, Chih-Sung
    Lee, Jia-Fu
    Chen, Chia-Chi
    Chang, Yue-Cune
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 56 : 52 - 57